Home 2017-05-29T17:02:20+00:00

Transporting Therapeutics into The Brain

biOasis Technologies Inc. has developed and is now commercializing a ground-breaking platform for the delivery of therapeutic compounds across the blood-brain barrier and into the Central Nervous System for the treatment of neurological diseases, including, but not limited to, brain cancers, neurodegenerative and metabolic diseases. With the ability to transport therapeutics of almost any type and size across the blood-brain barrier, the Transcend Platform is now available to be licensed by biotechnology and pharmaceutical companies for the advancement of their neurotherapeutic programs.

 

The Transcend Platform

The Transcend Platform consists of a diverse suite of peptide carriers and linkers that together provide transport solutions for a host of CNS therapeutics including monoclonal antibodies, enzymes, small molecules and various types of gene therapies.

Designed to deliver high concentrations of therapeutics into the CNS with minimal dosing requirements and with no disruption of the blood-brain barrier, The Transcend Platform is based on Receptor Mediated Transcytosis, nature’s own method of carrying compounds into the brain. The Transcend Platform has achieved an exceptionally high success rate in the transport of dozens of compounds across the BBB in both in vitro and in vivo studies at over twenty third-party institutions and corporations. The studies illustrate that the Transcend Peptide does not materially affect either the half-life or efficacy of the transported therapeutics. Data from many of these studies are available for review by pharmaceutical and biotech corporations and institutions.

Licensing Opportunities

biOasis has developed flexible licensing models that allow pharmaceutical companies and biotechs to advance and commercialize their neurotherapeutic pipelines. The Transcend Platform’s comprehensive patent structure provides licensees with exceptional protection of their intellectual property and with the opportunity to further protect fusion proteins and conjugates developed within the terms of their biOasis Transcend Platform licenses.

Recent News

biOasis Announces Voting Results for 2017 Annual Meeting

Thursday, September 21, 2017|Comments Off on biOasis Announces Voting Results for 2017 Annual Meeting

The Company welcomes new board members Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan

Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the meeting was 17,212,451, representing 33.45% of the total issued and outstanding biOasis shares.

All directors nominated by management were approved, including new members Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D., and Maha Radhakrishnan, M.D. as well as returning members Rob Hutchison (Chairman, founder and former chief executive officer), Mark Day, Ph.D. (CEO), Ron Erickson and Michael Hutchison, QC. Messrs. Gubitz, Pearson and Fibiger were not nominated for re-election to the board at the AGM.  The Company wishes to thank Messrs. Gubitz, Pearson and Fibiger for all of their efforts on behalf of the Company. As previously announced, Michael Hutchison will step down from the board in October and Rob Hutchison will retire from the company on Dec. 31, 2017.

In addition to the new board slate, the shareholders approved the option & restricted stock unit (RSU) plans.

Election of Directors

All seven (7) candidates nominated for election to the biOasis Board of Directors and listed in the Company’s Management Information Circular, dated Aug. 21, 2017, were elected by a majority of the shareholders present in person or represented by proxy at the meeting. The voting results are as follows:

 

NAME VOTES FOR (%) VOTES WITHHELD (%)
Robin Hutchison 15,587,366 (91) 1,620,085 (9)
Mark Day, Ph.D. 17,207,451 (99.9) 0 (0)
Mahalakshmi Radhakrishnan, M.D. 17,146,951 (99.6) 60,500 (<0.01)
Deborah Ann Rathjen, Ph.D. 17,147,451 (99.6) 60,000 (<0.01)
Nancy E. Stagliano, Ph.D. 17,207,451 (99.9) 0 (0)
Ronald P. Erickson 16,016,866 (93) 1,190,585 (7)
J. Michael Hutchison, QC 15,617,366 (91) 1,590,085 (9)

 

Compensation Committee

Nancy Stagliano, Ph.D. (chair), Deborah Rathjen, Ph.D. and Mark Day, Ph.D. have been appointed to the Compensation, Governance and Nominating Committee.

Audit Committee

Deborah Rathjen, Ph.D. (chair), Mahalakshmi Radakrishnan, M.D. and Ronald Erickson have been appointed members of the Audit Committee.

Appointment of Auditors

biOasis also announced today that its shareholders have approved the re-appointment of Manning Elliott LLP, Accountants and Business Advisors as the Auditor of biOasis to hold office until the next annual meeting of shareholders.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing the xB3 platform, biOasis’ proprietary blood-brain barrier delivery technology, to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. BiOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day
President & Chief Executive Officer
biOasis Technologies, Inc.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Company Contacts

Catherine London
Catherine@bioasis.us
+1 917 763 2709

Graeme Dick
info@bioasis.us
+1 403 561 8989

biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member

Monday, September 18, 2017|Comments Off on biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member

Additional Board & Leadership Team Changes Also Announced

Sept. 18, 2017

Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announces that Rob Hutchison, biOasis founder, former chief executive officer and current chairman of the board of directors (BoD), will retire as chairman and board member, effective Dec. 31, 2017. Board member Michael Hutchison will also step down from the biOasis BoD in October 2017.

“Rob first informed me that he was ready to step down early on in my interview process. I convinced him to stay on to help transition the company to my leadership team and it is with a heavy heart that we now make this announcement publicly,” said Mark Day, Ph.D. “I am grateful for Rob’s support and guidance. He is great person, a big thinker, an innovator and a great friend. I will miss working with Rob.”

“Michael has kindly offered to remain on the board until a suitable replacement candidate is identified in October,” said Dr. Day. “I would like to take this opportunity to publicly thank Michael for his unwavering support since I joined the company.”

The Company recently announced the nominations of three exemplary, world-class biotech and pharmaceutical executives to the board of directors. “Dr. Maha Radhakrishnan, Dr. Deborah Rathjen and Dr. Nancy Stagliano are formidable executives and are 100 percent committed to actively working to help shape the company,” said Dr. Day. “I really look forward to working with them and learning from their experiences. I have had several conversations with each of them regarding their participation on the BoD. They will work to drive the company forward with the same vigor, strategic prowess and tactical execution as they have in their other companies. I encourage our shareholders to vote with management in their nominations.”

“I am incredibly proud of all that we have achieved over the past 10 years since I founded biOasis, and I have great confidence in the future of the Company,” said Rob Hutchison. “Since my retirement as CEO in April 2017, it has been highly gratifying to continue to work closely with the board and new leadership team as chairman. “I look forward to spending more quality time with my family, and also exploring new and different opportunities. I would like to thank each and every one of the biOasis leadership team and our shareholders for their support. I am extremely grateful to the previous and current employees of biOasis and I am confident that they will continue to identify the latest cutting edge approaches to aid the  discovery and development of new breakthrough therapies for patients suffering with currently untreatable neurological diseases and disorders.”

Additional Leadership Changes

  • Chief Scientist Dr. Reinhard Gabathuler is no longer with the Company. Dr. Gabathuler has been great to work with and we wish him the best in his future endeavors. Dr. Day will serve as chief scientist, effective immediately, with support from the newly formed scientific advisory board (SAB) and Dr. Mei Mei Tian; Dr. Tian has been promoted to vice president of external research;
  • Warren K. Volles, Esq. from IPraxus Legal, LLC has been retained to lead the Company’s intellectual property strategy as well as to maintain and expand the Company’s current IP portfolio, among other responsibilities;
  • The Company is actively seeking to hire a seasoned chief financial officer (CFO) with biopharmaceutical experience as well as global market and capital raising capabilities. CFO interviews are underway and an announcement is expected in the next couple of weeks; and
  • Additions to the BoD and SAB are also pending.

The biOasis leadership team will work with the BoD and SAB to inform, implement and oversee the Company’s licensing activities, and improve the execution of the biOasis alliances, business development and research and development programs. “Our leadership team is well positioned to ensure the right fit and find ways to leverage our institutional knowledge and experience as we look toward new collaborations. Personally, I consider this to be one of the most capable business and scientific teams I have ever worked with,” said Dr. Day.

About Warren K. Volles, Esq.

Warren K. Volles, Esq., founder of IPraxus Legal, LLC. provides businesses with alternatives for handling their intellectual property (IP) needs. For over 25 years, Warren K. Volles, Esq. has provided legal advice on IP matters to some of the world’s foremost multinational companies both as corporate counsel and in private practice. He was previously the assistant general counsel at Bristol Myers Squibb and also was responsible for managing their IP and conducting due diligence in licensing and mergers and acquisitions.

Apart from his registered practice before the U.S. Patent and Trademark Office (USPTO), Volles is admitted to practice law in the states of Connecticut, New York and Rhode Island. Volles has drafted and prosecuted hundreds of patent applications and has taken cases through appeal in the U.S., Europe, Japan, China, India and other jurisdictions. Moreover, he shares great camaraderie with highly competent law firms across the world to ensure his Clients have the right person for the job regardless of the issue at hand-patent procurement, oppositions, defense, infringement and agency interaction.

Transactions involving intellectual property-acquisitions, divestitures, licensing and collaborations – as well as regulatory strategy and interaction with government agencies are within Volles’ expertise. Volles is experienced at managing large patent portfolios, attorneys, staff and systems within an organization, and the strategic development of IP estates, through discovery, development and commercialization of products.

Volles earned his bachelor of science degree in chemical engineering and material science from the University of Connecticut and his juris doctor degree from the Pace University School of Law.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing the xB3 platform, biOasis’ proprietary blood-brain barrier delivery technology, to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day
President & Chief Executive Officer
biOasis Technologies, Inc.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Company Contacts

Catherine London
Catherine@bioasis.us
+1 917 763 2709

Graeme Dick
info@bioasis.us
+1 403 561 8989

biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform

Thursday, September 7, 2017|Comments Off on biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform

Distinguished Research & Development Scientists Prof. John H. Krystal, M.D., Jeffrey L. Cummings, M.D. and John P. Wikswo, Jr., Ph.D. Appointed as Inaugural Members

World-renowned Psychiatrist Dr. Krystal will Serve as Chair of the SAB

Sept. 7, 2017

VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;TSX.V:BTI), a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced the appointments of Prof. John H. Krystal, M.D., Jeffrey L. Cummings, M.D. and John P. Wikswo, Jr., Ph.D. to its newly established Scientific Advisory Board (SAB). These independent experts will serve as a strategic resource to biOasis as it continues to advance the company’s proprietary drug delivery platform. Dr. Krystal will serve as chairman of the SAB.

“I’m excited to serve as chair of the biOasis SAB and to work with Mark again,” said Dr. Krystal. “Most drugs created to treat central nervous system diseases and disorders fail because they aren’t optimally designed to be delivered in sufficient quantities to the brain. I look forward to working with Mark and his team to untap the potential of the biOasis platform in the development of differentiated treatments for previously untreatable neurological diseases and disorders.”

Additional members will be added once their institutions approve their membership to the biOasis SAB. The SAB will be comprised of leaders from the academic, pharmaceutical and biotechnology industries from discovery, translational medicine and clinical development areas The SAB will work closely with the biOasis management team to advance the development of the Company’s proprietary BBB drug delivery platform, xB3. The role of the SAB is to provide strategic guidance and direction for the biOasis in-house development programs as well as strategic research alliances. The SAB will also play a role in guiding and prioritizing the company’s research investment.

“I am intrigued by the proprietary xB3 BBB drug delivery technology that biOasis has developed and I am eager to assist with the strategy for its development,” said Dr. Cummings.

“I am excited at the opportunity of working with biOasis and their SAB. This is translational science at its best — my academic research group received five years of funding from NIH/NCATS to develop a neurovascular unit on a chip and the supporting hardware. We learned a lot from our experiments, colleagues, pharma, and organ-on-chip companies, and are proceeding to develop on-chip disease models. Now I can help guide the development of a specific therapeutic platform,” said Dr. Wikswo.

“We are honored to welcome Dr. Krystal, Dr. Cummings and Dr. Wikswo to the new biOasis SAB. Having worked with Professors Krystal and Cummings previously, I’ve been fortunate to have had their guidance and support on several key studies. They helped guide my translational research during one of the most productive periods in my career. I can’t wait to work with them again. Dr. Wikswo adds significant BBB experience to our board. His work developing a BBB on a chip as part of his organs-on-a-chip program has been extraordinary and I look forward to working with him as well. They are all true leaders in their fields,” said Mark Day, Ph.D., president and chief executive officer, biOasis Technologies, Inc. “Our new SAB members will provide a tremendous knowledge base that will help to inform our approach to our ongoing research and clinical development activities. Their collective knowledge and guidance will be invaluable as we advance our in-house research programs and external research alliances.”

Professor John H. Krystal, M.D. is the Robert L. McNeil, Jr., professor of translational research, chair of the department of psychiatry, and professor of neuroscience at the Yale University School of Medicine and chief of psychiatry at Yale-New Haven Hospital. Dr. Krystal has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, post-traumatic stress disorder (PTSD) and depression. Notably, he led the discovery of the rapid antidepressant effects of ketamine in humans. Dr. Krystal is the director of the National Alcohol Abuse and Alcoholism Advisory Council Center for the Translational Neuroscience of Alcoholism and the Clinical Neuroscience Division of the VA National Center for PTSD. Dr. Krystal is a member of the U.S. National Academy of Medicine. Currently, he is president of the International College of Neuropsychopharmacology, a member of the National Institute of Mental Health National Mental Health Advisory Council and editor of Biological Psychiatry.

Dr. Krystal received his bachelor of science degree in behavioral sciences from the University of Chicago and his doctor of medicine degree from Yale University School of Medicine. He completed his residency in the Yale Psychiatry Residency Training Program.

Jeffrey L. Cummings, M.D., is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and Cleveland, the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and professor of medicine (neurology) at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is principal investigator/director of the National Institutes of Health/National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.

Dr. Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. He was featured in the Gentleman’s Quarterly (June 2009) as a “Rockstar of Science.” Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

Dr. Cummings was formerly professor of neurology and psychiatry at the University of California, Los Angeles (UCLA), director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association. Dr. Cummings has authored or edited 39 books and published over 700 peer-reviewed papers.

Dr. Cummings completed his neurology residency and a fellowship in behavioral neurology at Boston University, Boston. His U.S. training was followed by a research fellowship in neuropathology and neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London.

John P. Wikswo, Jr., Ph.D., is the Gordon A. Cain University professor at Vanderbilt University and is the founding director of the Vanderbilt Institute for Integrative Biosystems Research and Education. He has been on the Vanderbilt faculty since 1977. His research has included superconducting magnetometry, the measurement and modeling of cardiac, neural and gastric electric and magnetic fields and non-destructive testing of aging aircraft. In 1980, he and his group made the first measurement of the magnetic field of a nerve impulse.

As a tenured member of the departments of biomedical engineering, molecular physiology and biophysics, and physics and astronomy, he is guiding the development of microfabricated devices, optical instruments and software for studying how living cells interact with each other and their environment and respond to drugs, chemical/biological agents, and other toxins, thereby providing insights into systems biology, physiology, medicine and toxicology.

He has over 200 publications, is a fellow of seven professional societies, and has received 22 patents. He loves teaching and learning, and sharing his enthusiasm for research and inventing with high-school students, undergraduates and graduate students. He is happiest when he is tinkering and doing plumbing, carpentry and wiring, either on his house or the ones that he and his group are building to grow cells and miniature human organs. His group’s work on organ-on-chips focuses on the development of intelligent well plates that serve as perfusion controllers, microclinical analyzers and microformulators; developing a blood-brain barrier on a chip; and integrating multiple organs to create a milli-homunculus from coupled organs on chips. To learn more about the development of a microfluidic device containing human cells which can model the blood-brain barrier, visit: https://www.technologynetworks.com/neuroscience/videos/blood-brain-barrier-on-a-chip-29073

Dr. Wikswo trained as a physicist and he received his bachelor of arts degree from the University of Virginia, and his doctor of philosophy degree from Stanford University.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Mark Day, Ph.D.
President & Chief Executive Officer
biOasis Technologies, Inc.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contacts

Catherine London
Catherine@bioasis.us
+1 917 763 2709

Graeme Dick
info@bioasis.us
+1 403 561-8989

biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders

Monday, August 28, 2017|Comments Off on biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders

New Board nominees include accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc. 

biOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017

 

August 28, 2017

VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF;TSX.V:BTI) is pleased to announce its slate of nominees to the board of directors (the “Board”) for election at the annual general meeting of shareholders (the “Meeting”) on Thurs., Sept. 21, 2017. The slate is comprised of four current directors and three new nominees. The biOasis management team has nominated accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D. and Maha Radhakrishnan, M.D. for election to the Board at the Meeting.

biOasis founder Mr. Rob Hutchison will step down as chairman of the board on Dec. 31, 2017. “Rob has shown himself to be a real visionary, acquiring and securing new biOasis intellectual property (IP). He afforded the inception of biOasis in 2007, and led the company through April 2017. He has invested a great deal both personally and professionally into the company’s success and we would not be where we are today without his business insights, IP expertise and knowledge of the Canadian markets,” said Mark Day, Ph.D., president and chief executive officer, biOasis. “I am indebted to Rob for the opportunity to lead this organization and for the guidance and support he has given me since I started with biOasis. Rob created a company with a unique collaborative phenotype, a key ingredient to success.”

“Transitions like this are bittersweet, but I am confident this is the right time to begin to take this next step for biOasis’ future. Mark is a dynamic CEO who I believe will continue to lead the Company upward and implement successful growth driven by the new dual business strategy, “ said Rob Hutchison, founder, former CEO and board chairman of biOasis. “I am highly confident in the experience of these new board nominees and the counsel they will provide. I look forward to watching Mark and his executive team accomplish great things in the months and years to come with their guidance.”

“I am tremendously excited about our new Board nominees and the value they will bring to biOasis.  I believe these seasoned life science professionals will help accelerate the positive momentum forward that has begun. This is a group of well-qualified, experienced industry leaders. These nominees have held senior leadership roles in areas that are strategically relevant to our business, including global expansion, product development and mergers and acquisitions,” said Dr. Day. “I have been fortunate to work with Drs. Stagliano, Rathjen and Radhakrishnan through my previous work at BMS and Alexion. If elected, I am confident they will act independently and in the best interest of the biOasis shareholders and the Company. These nominees are highly driven individuals with uncompromised standards for ethics and compliance. They have displayed brilliant leadership skills and exceptional values.”

Dr. Stagliano has a notable track record of leadership and innovation in the biotech industry. As a chief executive officer with three consecutive therapeutics company successes, Dr. Stagliano has demonstrated a strong formula for drug discovery and development, fundraising and M&A. Dr. Stagliano transformed iPierian, Inc. from a platform to product company, resulting in its acquisition by Bristol-Myers Squibb and subsequent development of its neurodegenerative disease antibody by Biogen. Dr. Stagliano’s most recent company, True North Therapeutics, was acquired in June 2017 by Bioverativ based on the discovery and development of a breakthrough therapy for complement-mediated orphan diseases.

Dr. Rathjen has proven to be a skilled dealmaker and builder of alliances with her work on the Bionomics and Merck collaborations related to Alzheimer’s disease and other neurodegenerative and psychiatric diseases with the goal to improve cognitive dysfunction in neurodegeneration. The company also has an oncology pipeline.

Dr. Radhakrishnan brings significant global, medical and scientific expertise via her medical affairs leadership roles. Her relevant experience includes strategic collaborations in research, with the most recent example for advanced imaging between Bioverativ and Invicro. Dr. Radhakrishnan also has extensive product launch experience including blockbuster treatments at BMS, Cephalon, Biogen and Bioverativ. Dr. Radhakrishnan has significant experience across a broad range of therapeutic areas, including several diseases and disorders within CNS such as multiple sclerosis, Alzheimer’s disease, neuropathic pain, spinal muscular atrophy, schizophrenia, major depression, bipolar disorder, migraine, progressive supranuclear palsy and front temporal dementia.

“Their acceptance of these nominations further validates our science and supports our strategic business plans,” said Dr. Day. “biOasis will benefit from their business acumen and counsel as we look to advance the company.”

More About the Nominees

Nancy Stagliano, Ph.D.

Nancy Stagliano, Ph.D. is an accomplished serial biotechnology entrepreneur.  As chief executive officer, Dr. Stagliano has successfully launched and/or exited three consecutive biotech companies: CytomX Therapeutics (CTMX), iPierian and most recently, True North Therapeutics.  As Chief Executive Officer and co-founder of True North Therapeutics, Dr. Stagliano led the company to its recent acquisition by Bioverativ, Inc. for a total deal value of up to USD $825 million.  Under her leadership, True North discovered and developed a first-in-class monoclonal antibody in the classical complement pathway, TNT009, which received breakthrough therapy designation from the FDA for the orphan indication, Cold Aggultinin Disease. Previously, Dr. Stagliano was CEO of iPierian, Inc. which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of PSP and Alzheimer’s disease was acquired by BMS in April of 2014 for a total deal value of USD $725 million; the antibody is currently in a Phase 2 trial in PSP led by Biogen. From 2008-2010, Nancy was the CEO and co-founder of CytomX Therapeutics and a lead inventor on the CytomX Probody platform. Before moving to California, Nancy worked in Cambridge, Massachusetts where she had an eight-year tenure at Millennium Pharmaceuticals. Dr. Stagliano received her bachelor of science degree in electrical engineering and master of science degree in biomedical engineering from Drexel University in Philadelphia. She obtained her doctor of philosophy degree in neuroscience from the University of Miami, Miller School of Medicine in Miami.

Deborah Rathjen, BSc (Hons), Ph.D., MAICD, FTSE

Dr. Rathjen is the chief executive officer and managing director at Bionomics. Dr. Rathjen joined Bionomics in 2000 from Peptech Limited, where she was the general manager of business development and licensing. Under Dr. Rathjen’s leadership, Bionomics has advanced treatments for several CNS disorders, such as anxiety, depression and Alzheimer’s disease. The company also has a development program in oncology targeting cancer stem cell therapies in solid tumors. The Company’s technologies include ionX and MultiCore. Bionomics operates in three geographical areas, including Australia, France and the United States.

Dr. Rathjen was a co-inventor of Peptech’s TNF technology and leader of the company’s successful defense of its key TNF patents against a legal challenge by BASF. Dr. Rathjen has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization. Dr. Rathjen has been recognized both in Australia and internationally through awards and honors including the 2004 AusBiotech President’s Medal, 2006 Flinders University Distinguished Alumni Award, 2009 BioSingapore Asia Pacific Biotechnology Woman Entrepreneur of the Year, 2009 Regional Finalist Ernst & Young – Entrepreneur of the Year, and 2014 Woman Executive of the Year BioPharm Industry Awards. Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia and her bachelor of science degree in immunology from Flinders University in Adelaide, Australia.

Maha Radhakrishnan, M.D.

Dr. Radhakrishnan is a senior vice president and head of worldwide medical at Bioverativ Therapeutics Inc. in Waltham, Mass. Dr. Radhakrishnan brings a broad perspective from clinical practice, medical affairs, launch of block buster products, managed care, alliance management and business development. Dr. Radhakrishnan is a senior leader with extensive pharmaceutical, biotech and managed care industry experience covering clinical development, post-marketing regulatory activities, medical affairs, safety and reimbursement requirements. Dr. Radhakrishnan received her medical doctor degree in internal medicine with honors from the People’s Friendship University in Moscow, Russia. 

biOasis Technologies, Inc.’s Annual General Meeting of Shareholders

The Meeting is scheduled for 10 a.m. PDT on Thurs., Sept. 21, 2017 at:
Tanya Markovich Law Corporation 1780-400 Burrard Street Vancouver, BC V6C 3A6

The management information circular and other proxy materials for the Meeting will be mailed to shareholders and will be available on SEDAR, www.sedar.com, and under the Investors section on www.bioasis.ca today.

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Mark Day, Ph.D., President & Chief Executive Officer
biOasis Technologies, Inc.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

 

Company Contacts

Catherine London
Catherine@bioasis.us
+1 917 763 2709

 

Graeme Dick
info@bioasis.us
+1 403 561-8989

biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer

Monday, August 21, 2017|Comments Off on biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer

Williams bring significant experience in working with both large, multinational pharmaceutical companies & start-up biotechnology alliances

August 21, 2017, Vancouver, BC

VANCOUVER, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Doug Williams, MBA, as executive vice president, chief business officer, effective immediately. Williams will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, Williams will provide leadership and execute on the corporate development strategy that will maximize benefits for strategic partners and shareholders. Williams will be responsible for leading corporate and business development, as well as the alliance management efforts at biOasis.

“We are delighted to welcome Doug Williams to our senior management team at biOasis. I know he will bring value as a business development leader and well-respected and strategic alliance professional,” said Dr. Day. “Doug will play a critical role in advancing our partnering strategy and create value through the prosecution of licensing opportunities for our proprietary blood-brain barrier drug delivery platform.”

Williams has more than 20 years of experience in the pharmaceutical and healthcare industries and has successfully led cross-functional, global alliances teams across multiple organizations.  His alliance and partnering experience includes a broad set of partners including large, multinational pharmaceutical companies, as well as start-up biotechnology companies, which included global alliances with Shionogi, Exicure, AbbVie, Mylan and Takeda, among others.

Williams has been recognized as an industry leader who has presented, participated as a panelist, and moderated multiple industry partnering programs at industry events.

“Doug has a broad set of experiences having worked in leadership roles at healthcare technology start-ups, pharmaceutical and biotechnology companies. His diverse experience base will help propel our global partnering efforts,” said Rob Hutchison, founder and chairman of the board of directors. “Doug will be a great addition to the biOasis leadership team.”

Williams most recently came from Purdue Pharma L.P where he worked on strategic alliances and business development projects related to clinical and pre-clinical programs. Prior to Purdue, Williams built his own successful consulting business working with start-up healthcare technology companies.  Doug’s experience includes commercial sales, sales management, alliance management and business development.  He has also held various positions of increasing responsibility at Pfizer, Johnson & Johnson, Elan, Sepracor and Kadmon over his 20 year career.

“I am eager to work with Mark on shaping the business strategy for biOasis as we continue to advance our proprietary blood-brain barrier technology platform,” said Williams. “I want to thank Rob and Mark for this opportunity. I look forward to sharing the biOasis story with new potential collaborators and leading the licensing and partnering efforts on behalf of the company and our shareholders.”

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system diseases and disorders. The company maintains headquarters in Vancouver, Canada with offices in Connecticut, United States. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day, President and Chief Executive Officer

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

 

Company Contacts

Catherine London
Catherine@biasis.ca
+1 917 763 2709

Graeme Dick
info@bioasis.ca
+1 403 561-8989

biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations

Sunday, June 25, 2017|0 Comments

pdficon_small Download this as a PDF

June 26, 2017, Vancouver, BC

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, London will have responsibility for leading all external communications, corporate visibility, brand-building, reputation management, financial communications and investor relations.

“The Board of Directors and I are delighted to welcome Catherine London to our senior management team at biOasis. Having worked with Catherine previously, I know she is a forward-thinking communications leader and collaborative relationship builder,” said Dr. Mark Day. “She will play a critical role in the strategic design and execution of communications and investor relations initiatives to drive business growth. I look forward to working with her again.”

“Catherine brings with her the broad pharmaceutical and biotechnology industry expertise and experience we are looking for to help propel biOasis globally,” said Rob Hutchison, founder and chairman of the board of directors. “She will be an instrumental member of the team.”

London has more than 22 years of experience in the pharmaceutical and healthcare industries and has successfully led large, global teams and strategic plans. London most recently served as the head of corporate communications at Purdue Pharma L.P. Prior to Purdue, London served in director-level roles in corporate and product communications at Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. In these roles, her responsibilities included executive, corporate, product and financial communications, government and policy communications and business communications. London has also held senior leadership roles at global consulting firms such as the Chandler Chicco Companies, an inVentiv Health Company, which includes Chamberlain, Chandler Chicco and BioSector2, and at Ruder Finn.

“I believe in Mark’s vision and business strategy for biOasis as well as the promise of the in-house programs and Transcend platform. This is truly an exciting time in the neuroscience field and we have a great story to tell at biOasis,” said London. “I want to thank the board of directors, Rob Hutchison and Mark for this opportunity. I look forward to leading the communications and investor relations on behalf of the company and its shareholders.”

London began her career as a reporter and editor working at print and broadcast outlets in various U.S. markets before taking a turn as a science journal editor and eventually making the transition to public affairs at the American Diabetes Association. London holds a bachelor of arts degree in journalism from Auburn University in Auburn, Ala.

About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company with offices in Canada and the U.S., focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,, “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day, President and Chief Executive Officer

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Company Contact
Graeme Dick
biOasis Technologies Inc.
info@bioasis.ca
1- (403) 561-8989

biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

Thursday, June 15, 2017|0 Comments

pdficon_small Download this as a PDF

June 15, 2017, Vancouver, BC

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally.

The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The value in Transcend is the potential to turn non-brain-penetrant drugs into novel medical entities, to deliver them to the brain and to treat a range of disorders (e.g., oncology, lysosomal disorders and neurodegenerative diseases). Therefore, Transcend has the potential to treat more than one hundred identified brain and other CNS disorders.

Non-dilutive funding is available for many of these disorders from multiple government and private sources. FreeMind Group has the expertise to identify these funding sources and to assist biOasis throughout the funding process, from the preparation and submission of funding applications to pre-award negotiations.

“As we advance our internal programs, it is important to continue to drive new scientific discoveries and understand which diseases the Transcend platform may best serve. To this end, Freemind is an important strategic addition to our armamentarium. Dr. Reinhard Gabathuler, chief scientist, biOasis, will manage this collaboration,” said Dr. Mark Day, chief executive officer.

“FreeMind can play an important dual role for us, both protecting shareholder value and helping biOasis identify potential diseases and translational endpoints of interest,” said Dr. Day. “Much of the work we will conduct fits well within the mandate of many organizations that provide this type of non-dilutive funding. FreeMind has a strong track record and is highly regarded by academia, industry, and the funding organizations. This should provide biOasis with greater opportunities for success in the grant funding process.”

About FreeMind
Established in 1999, FreeMind is the largest consulting group of its kind working with academics and industry alike. FreeMind assists in maximizing potential to receive funding from non-dilutive sources such as the NIH, DOD, NSF, FDA, BARDA, as well as private foundations. FreeMind assists in the guiding of non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. FreeMind has garnered its clients over $1.5 billion to date. Awards range from $150,000 to $150million per project.

About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day, CEO

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”

Company Contact
Graeme Dick
biOasis Technologies Inc.
info@bioasis.ca
1 (403) 561-8989

biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders

Wednesday, June 14, 2017|0 Comments

pdficon_small Download this as a PDF

June 14, 2017, Vancouver, BC

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) Dr. Mark Day, chief executive officer, has issued a message to shareholders detailing plans for the advancement of the Transcend Platform and the company’s in-house programs.

To the Shareholders of biOasis Technologies Inc.:

As the new CEO of biOasis, I am delighted to send my first message to shareholders, especially at a time when there is such excitement in the neurosciences. Scientists are beginning to understand the surreal complexity of the central nervous system (CNS), how to explore further into its mysteries, to understand its workings, diagnose its diseases, and how to accurately monitor the progress of CNS diseases and the efficacy of the drugs that treat them.

I and my many friends and colleagues in the industry are moving ahead on many fronts. Celgene and Vertex have recently moved into the CNS arena under the guidance of two exceptional R&D leaders. In 2014 the Nobel Prize in Physiology or Medicine was awarded to a team that made breakthrough discoveries on spatial memory, discoveries that have informed my own work.

Several significant breakthroughs were made in the last year. The most exciting for me was with Alzheimer’s disease. Biogen demonstrated their aducanumab could slow the progression of Alzheimer’s disease in mild-to-moderate patients. This truly was a first and shows that when you prioritize science, you can yield truly astounding results.

And now, as CEO of biOasis, I find myself right in the middle of this new era in neuroscience with what I have previously called, “one of the most unique and promising blood-brain barrier technologies of our time.” Despite all the advances in neuroscience, the ability to transport drugs across the blood-brain barrier has remained elusive, something I believe biOasis and our Transcend Platform can address.

During the past few weeks, I have completed assessments of the Transcend Platform, the studies and data relating to the platform, the company’s Transcend patent portfolio and the two business models developed by the company. I have come away from this process more excited than ever. I believe the Transcend Platform, with its unique abilities, simplicity and comprehensive intellectual property (IP) protection, enables the two business models, and that the company should immediately move forward with them.

In the remainder of this first letter to shareholders, I will discuss the company’s internal clinical programs. In a future message, I will similarly discuss the company’s licensing model. I believe it is important for the pharmaceutical industry to keep pace with biOasis with respect to the delivery of drug candidates across the BBB and into the CNS. The Transcend licensing model will allow our future licensees to do that.

We Are a Science-Focused and Science-Driven Company.
Our focus is to do the right studies, at the right time, for the right reasons, a focus designed to bring success. We must avoid the mistake of rushing into clinical studies until we are certain we have the right endpoints. Otherwise we will succumb to the same issues that have led to the collapse of many biotech companies before us. Our studies and trials must have the right “go” or “no-go” endpoints.

The value in Transcend is the potential to turn non-brain-penetrant drugs into novel medical entities, to deliver them to the brain and to treat a range of disorders across oncology, lysosomal disorders and neurodegenerative diseases. A drug that did not treat the neurological aspects of a disease but can now be non-invasively delivered to the brain is not just a “bio-better,” it is a differentiated product.

In the immediate near term, our aim is to select, in a disciplined manner, the best assets to take into patients. This is not something to be undertaken without due consideration. We need to ensure the drugs have the following characteristics:

  • Target Engagement: The drug must reach its target in the brain (e.g., brain metastasis/glioblastoma) in sufficient quantities to be able to test the hypothesis in the clinic. Most drugs fail because they fail to get enough of the drug to the target.
  • Pharmacodynamic Activity: Once at its destination in the brain, the drug/target interaction should drive a biological consequence (e.g., in schizophrenia this could be the reduction of dopamine, a brain chemical that is excessive in the disease).
  • Patient Selection: We must ensure we have the right patient population to test.

Our plan is to utilize non-invasive, non-human primate (NHP) brain imaging to assess eight targets (across oncology, rare diseases and neurological indications) for their ability to get to the needed site of action in the brain. Only those targets showing actual target engagement will advance into phase 0 microdosing studies. This means we advance only those drugs where we see significant uptake in NHP imaging. The drugs with the best brain uptake will be prioritized for their use in human phase 0 studies.

Details of these studies will be released when our plans are completed. The NHP studies will not directly impact the previously discussed phase 0 clinical trial in oncology. We have already selected a manufacturer to produce the clinical-grade fusion proteins required for the study. The development of the cell line to produce the fusion protein and the manufacturing of the required quantity of the drug will take up to a year to complete.

It’s also essential to recognize one of the main receptors Transcend utilizes to trick the brain into opening the BBB is expressed in important regions of the brain, including areas critical to learning, memory, mood and impulsivity. This receptor is significantly expressed in glioblastomas and in key areas of the brain involved in a plethora of psychiatric and neurological diseases. I think these represent very intriguing targets for biOasis.

With respect to our in-house programs, it is essential for biOasis to have access to the best scientific advice available. To that end, we are currently creating a Scientific Advisory Committee with its members to be chosen from among the world’s top scientists. We are also assessing our internal expertise and management requirements. In the very near future, I expect to be making announcements about strategic appointments to address those requirements.

The biOasis in-house programs are a major undertaking. They are being developed in a robust scientific manner, with meaningful targets chosen to help ensure success. That success could produce ground-breaking results and could herald a broadly-recognized new era in neuroscience. I believe it’s possible, and that’s why I want to be right here at biOasis, and nowhere else.

In my previous roles in pharma, I have passionately driven research and development (R&D) and business development (BD) programs and I have succeeded in delivering new innovations to the R&D and BD processes. As CEO, I intend to bring the same dedication and vision to biOasis.

I want to thank the Executive Chairman, the Board of Directors and all our shareholders for this opportunity. Together we will accomplish great things and I look forward to working with you.

Sincerely,

Mark Day, Ph.D.
Chief Executive Officer
biOasis Technologies Inc.

About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Rob Hutchison, Chairman of The Board of Directors

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contact
Graeme Dick
biOasis Technologies Inc.
info@bioasis.ca
1- (403) 561-8989

biOasis to Present at The Global Chinese Financial Forum – Shanghai Conference 2017

Thursday, June 8, 2017|0 Comments

pdficon_small Download this as a PDF

June 8, 2017, Vancouver, BC

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day.

Dr. Day’s presentation, “A Ground-Breaking Platform for the Delivery of Therapeutic Compounds Across the Blood-Brain Barrier,” will be attended by a wide assortment of private investors, life science companies and investment funds. The GCFF – Shanghai Conference 2017 will be held concurrently with China’s largest pharma-focused event, the CPhI China Conference.

“The Chinese pharmaceutical industry is one of the largest in the world with double-digit growth and exceptional opportunities for biOasis,” said Dr. Mark Day, CEO, biOasis. “The GCFF – Shanghai Conference 2017 offers biOasis the opportunity to introduce our Transcend Platform to executives and scientists from many of China’s largest life science companies and to begin building alliances throughout Asia.”

“On a personal note, the conference is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward,” said Dr. Day. “I have described Transcend as one of the most unique and promising blood-brain barrier technologies of our time. I look forward to meeting my industry colleagues and establishing new ones, placing biOasis in the mix of growth opportunities the Chinese pharmaceutical industry can offer us.”

About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Rob Hutchison, Chairman of The Board of Directors

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contact
Graeme Dick
biOasis Technologies Inc.
info@bioasis.ca
1- (403) 561-8989

biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders

Sunday, June 4, 2017|0 Comments

pdficon_small Download this as a PDF

June 4, 2017, Vancouver, BC

BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07 – 10, 2017.

Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets issues relating to therapies to treat the central nervous system (CNS). The workshop is academic in nature and will be attended by scientists from companies and institutions that are focused on lysosomal storage diseases.

Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders, some of which cause significant impairments in neurological function. The disorders are caused by dysfunctional or missing enzymes that are required for the processing and removal of unwanted cellular materials.

Several LSDs can be treated with enzyme replacement therapy, the intravenous infusion of a solution containing the missing enzyme. However, the blood-brain barrier blocks most therapeutics, including enzymes, from entering the CNS in sufficient quantities to effectively treat neurological disorders. The inability of most therapeutics to enter the CNS has resulted in areas of great unmet medical need.

“Our Transcend peptide technology specifically addresses the issue of delivery of therapeutics across the blood-brain barrier,” said Dr. Mark Day, CEO of biOasis. “From the preclinical data we’ve generated to date, we are excited to move several targets, including enzymes, antibodies and small molecules, through de-risking imaging studies and into clinical assessment. This workshop allows me to meet with many of the stakeholders in this very key market for us.”

About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the brain-blood barrier. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company, please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Dr. Mark Day, CEO

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contact
Graeme Dick
biOasis Technologies Inc.
info@bioasis.ca
1- (403) 561-8989

When Transcend was conjugated with Trastuzumab it was shown in vivo to deliver Trastuzumab across the BBB and into the brain.
Read more…

Antibodies directed at Aβ could offer therapeutic opportunities for reducing amyloid plaques in the brain for a potential treatment in Alzheimer’s disease.
Read more…

Lysosomal storage diseases (“LSD”) are rare inherited metabolic diseases caused by a defective gene that result in an enzyme deficiency in lysosome cellular structures.
Read more…

Small-Interfering RNA (siRNA) is a gene silencing technology which can be used to reduce the expression (commonly called a “knock-down”) of specific disease causing genes.
Read more…

PARTNER NETWORK